Alignment Healthcare
Tech-enabled Medicare Advantage insurer using AI-driven claims and risk scoring to grow fast.
On the record
Checkpoint: Q2 2026 earnings and update on whistleblower capex/opex misclassification claims
The call
Alignment is growing fast and just turned profitable, but a whistleblower claim now puts that profitability story under formal investigation.
Alignment Healthcare is an insurance company that focuses on older adults on Medicare, and it made money for the first time in 2025 after years of losses. It uses artificial intelligence to speed up claim decisions and has built relationships with local doctors and hospitals, which are harder for competitors to copy quickly. However, a whistleblower claimed in July 2026 that the company may have hidden expenses to make profits look bigger, which triggered government investigations and caused the stock to drop sharply, creating doubt about whether the company is actually as profitable as it says. The real test will come when the company reports earnings and regulators finish their investigations, because if the accounting problems are real, the company's turnaround story falls apart.
Why
01
Bigger players: UnitedHealth/Optum, Humana/CenterWell, Aetna/CVS, Elevance. Bigger insurers move slowly but face no rule stopping them from copying Alignment's data and network playbook over time. Could a giant copy it? Yes, easily.
02
What protects it. CMS licensing, local provider networks, and proprietary risk data make its coding edge hard to copy fast.
What would change this call
Q2 2026 earnings release on July 30, 2026. Shows whether reported profitability holds up under scrutiny after the whistleblower allegations.
Resolution of the three securities investigations tied to the July 8, 2026 whistleblower claim. Determines whether capex/opex misclassification allegations are dismissed or confirmed.
Outcome of Alignment v. CMS star-ratings litigation (~$50M at stake for 2027 payments). Indicates whether regulatory rulings will erode near-term revenue.
Resolution of the three securities investigations tied to the July 8, 2026 whistleblower claim. Determines whether capex/opex misclassification allegations are dismissed or confirmed.
Outcome of Alignment v. CMS star-ratings litigation (~$50M at stake for 2027 payments). Indicates whether regulatory rulings will erode near-term revenue.
Key numbers
- FY2025 revenue $3.95B, up 46.1% YoY
- First profitable full year, Adjusted EBITDA $110M
- Stock fell 17% after July 8 whistleblower allegation
Named risks
- Whistleblower lawsuit alleges opex/capex misclassification inflating 2024-2025 Adjusted EBITDA.
- Three law firms investigating potential securities violations as of 2026-07-22.
- CMS risk-adjustment model reset expected by ~2029 could erode coding-based margin advantage.
- Pending CMS star-ratings litigation outcome uncertain, ~$50M in bonus payments at stake.
- CEO and executive insider stock sales continue during active litigation overhang.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| UnitedHealth/Optum | contesting | Alignment grew members 30.9% YoY by 2026-03-31 despite incumbent's national scale |
| Humana/CenterWell | contesting | Alignment's 98-100% of members in 4-star+ CMS plans for 2026 challenges incumbent star performance |
| CVS Health/Aetna | contesting | Alignment expanding to new states for 2027-2028 as reported 2026-06-10 while incumbents face MA margin pressure |
| Clover Health | gaining on | Alignment's ~285,000 members by 2026-03-31 dwarfs Clover's smaller, more concentrated base |
| SCAN Health Plan | contesting | Co-filed CMS star-ratings lawsuit 2026-07-14 as similarly sized regional MA peer |
Questions people ask
- Is Alignment Healthcare profitable in 2026?
- Yes. FY2025 was the company's first full profitable year, with revenue of $3.95 billion, up 46.1% YoY, reported February 26, 2026. Q1 2026 EPS came in at $0.05 versus $0.01 consensus, and full-year 2026 revenue guidance sits at $5.16-5.21 billion as of May 1, 2026.
- Is Alignment Healthcare facing a fraud investigation?
- Yes. On July 8, 2026, former chief transformation officer Hakan Kardes filed a whistleblower lawsuit alleging Alignment misclassified operating expenses as capital expenditures to inflate Adjusted EBITDA for 2024-2025. Shares fell about 16.7% on the news, and three law firms opened securities investigations by July 22, 2026.
- Who are Alignment Healthcare's biggest competitors?
- Alignment competes with national Medicare Advantage giants UnitedHealth/Optum, Humana/CenterWell, CVS Health/Aetna, and Elevance, plus smaller tech-enabled peers like Clover Health and nonprofit SCAN Health Plan, which co-filed a CMS star-ratings lawsuit with Alignment on July 14, 2026.
- Could AI replace Alignment Healthcare?
- No. Alignment is a CMS-licensed, risk-bearing insurer, a regulatory status AI tools cannot assume. Its proprietary AVA platform, built over 10-plus years using 200+ data sources and 13,000+ attributes, is an internal AI asset supporting the business, not a substitute for its licensing, provider networks, or underwriting role.
- Is it risky to join Alignment Healthcare right now?
- There is active uncertainty: a July 8, 2026 whistleblower lawsuit alleges EBITDA-inflating accounting misclassification, prompting three securities-law investigations by July 22, 2026, and a pending CMS star-ratings lawsuit over roughly $50 million in denied bonus payments. Growth metrics remain strong, with Q1 2026 membership up 30.9% YoY.
- Is Alignment Healthcare publicly traded and who controls it?
- Alignment Healthcare trades on Nasdaq as ALHC. It IPO'd on March 26, 2021, pricing 27.2 million shares at $18.00 and raising about $390.6 million. There is no parent company; CEO John Kao, who founded it in 2013, continues to sell shares under 10b5-1 plans, including 298,000 shares worth $6.07 million in June 2026.
Timeline
- 2026-07-22Kaplan Fox reminder notice; third law firm investigating potential securities violations
- 2026-07-14Alignment and SCAN Health Plan sue CMS over 2026 Star Ratings methodology, cite ~$50M denied bonus
- 2026-07-08Whistleblower lawsuit alleges opex/capex misclassification inflating 2024-2025 Adjusted EBITDA, stock falls 16.7%
- 2026-05-01Q1 2026 earnings call, issues FY2026 revenue guidance of $5.16-5.21B
- 2026-04-30Q1 2026 results: revenue $1.24B, EPS $0.05 beats $0.01 consensus
- 2026-02-26FY2025 results: revenue $3.95B, up 46.1% YoY, first full profitable year
- 2026-01-12Membership growth reported at 31% YoY for 2025
- 2021-03-26IPO on Nasdaq, 27.2M shares at $18.00, raised $390.6M
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results (2026-02-26)
- ALHC Q1 2026 Earnings Report (2026-04-30)
- Alignment (ALHC) Q1 2026 Earnings Transcript (2026-05-01)
- Alignment membership grows 31% in 2025 (2026-01-12)
- Alignment Healthcare, Inc. Earnings Call Insights Q4 2025 (2026-04-17)
- Alignment Healthcare Outlook as MA Growth Fuels Margin Gains in 2026 (2026-07-06)
- Alignment Health eyes market expansion in 2027 (2026-06-10)
- Pioneering Value-Based Care Through Scalable Technology (2025-07-23)
- Reasons to Retain Alignment Healthcare Stock in Your Portfolio for Now (2026-07-16)
- ALHC INVESTOR ALERT: HBSS Launches Investigation (2026-07-15)
- Kaplan Fox Reminds Investors of Alignment Healthcare, Inc. (2026-07-22)
- SCAN, Alignment sue CMS over Medicare Advantage star ratings (2026-07-14)